Key Takeaways & Executive Findings
- •• Corrections to figures in the original paper do not alter the scientific conclusions. • The corrigendum provides corrected images for Figure 2B, Figure 5, and Figure 7. • The original study demonstrated that Vitamin B6 prevents Isocarbophos-induced posterior cerebral artery injury in offspring rats via up-regulating S1P receptor expression. • The corrected figures ensure accuracy and reproducibility of the published research.
Abstract
This corrigendum corrects errors in the original article 'Vitamin B6 prevents Isocarbophos-induced posterior cerebral artery injury in offspring rats through up-regulating S1P receptor expression' published in Acta Biochim Biophys Sin 2021, 53(12): 1691–1701. The errors were found in Figure 2B (Vit B6 + Fingolimod), Figure 5 (Saline), and Figure 7 (Isocarbophos/Control). The correct figures are shown. The authors apologize for the error. The corrigendum does not affect the interpretation of data and conclusions.
1. Introduction
This corrigendum addresses errors identified in the original research article titled 'Vitamin B6 prevents Isocarbophos-induced posterior cerebral artery injury in offspring rats through up-regulating S1P receptor expression' published in Acta Biochimica et Biophysica Sinica in 2021. The errors were found in specific figures: Figure 2B (Vit B6 + Fingolimod), Figure 5 (Saline), and Figure 7 (Isocarbophos/Control). The corrected figures are presented in this corrigendum to ensure the accuracy of the published data.
The authors sincerely apologize for these errors. Importantly, the corrections do not affect the interpretation of the data or the conclusions drawn in the original study. The original findings regarding the protective role of Vitamin B6 against Isocarbophos-induced posterior cerebral artery injury in offspring rats, mediated through up-regulation of S1P receptor expression, remain valid.
Loading authentic research manuscript (Pages 1–5)...
Yanhua Liu, Kunli Yang, Ling Wang, Jinfang Yang, Yang Wang, Hu Luo, Peng Li, Yaling Yin (2026). Corrigendum to: Vitamin B6 prevents Isocarbophos-induced posterior cerebral artery injury in offspring rats through up-regulating S1P receptor expression. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025088
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this corrigendum?
This corrigendum corrects errors in figures (Figure 2B, Figure 5, Figure 7) of the original article to ensure the accuracy of the published data.
Does the corrigendum affect the conclusions of the original study?
No, the corrigendum does not affect the interpretation of data or the conclusions of the original study.
What was the original study about?
The original study investigated the protective effect of Vitamin B6 against Isocarbophos-induced posterior cerebral artery injury in offspring rats, mediated by up-regulation of S1P receptor expression.
Which figures were corrected?
Figure 2B (Vit B6 + Fingolimod), Figure 5 (Saline), and Figure 7 (Isocarbophos/Control) were corrected.
Where can I find the corrected figures?
The corrected figures are provided in this corrigendum article.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.